Department of Neurobiology Special Lecture
Neurobiology
Clinical Biomarker Evidence for Target Engagement, Reduction of Synaptic Damage and Disease Modification in Alzheimer’s Patients Treated with CT1812 (Elayta™)
Susan Catalano, PhD
Founder and Chief Science Officer
Cognition Therapeutics, Inc.
January 28, 2020 - 9:30am
Victoria Hall 125